As of Dec. 31, 2025, Taelman said Nyxoah’s team was focused on 125 of the top 400 U.S. accounts. Within that group, the company trained 145 surgeons across 125 high-volume accounts. Nyxoah completed 120 Value Analysis Committee (VAC) submissions and had received 57 VAC approvals by quarter-end, with “no VAC rejections to date,” he said.Nyxoah received U.S. FDA approval for Genio on Aug. 8, 2025 and began actively launching the product, with “first implants and revenue as early as September 2025,” according ...

Financial Data and Key Metrics Changes - For Q4 2025, gross revenue was EUR 6.3 million before revenue deferrals of EUR 700,000, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [14] - Full year 2025 gross revenue was EUR 11 million before EUR 1 million of revenue deferrals, resulting in net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [15] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [14][15] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024, while the full year operating loss increased to EUR 83.5 million from EUR 58.8 million in 2024 [15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million in revenue generated from the first full quarter of launch [14][5] - 145 surgeons were trained in 125 high-volume hypoglossal nerve stimulation accounts, with 57 receiving positive Value Analysis Committee approval [5][7] Market Data and Key Metrics Changes - The company secured reimbursement for Genio across both Medicare and commercial payers, with Medicare representing 10% of the business and commercial payers approximately 90% [9][10] - The introduction of new C-codes for hypoglossal nerve stimulation by CMS is expected to facilitate billing and reimbursement processes [10] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - Plans for 2026 include expanding internal manufacturing to strengthen competitive position and improve gross margins [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, with expectations for U.S. net revenue to grow 25% sequentially in Q1 and Q2 2026 [16] - The company anticipates a strong financial profile as it gains market share in the U.S. [17] Other Important Information - The DREAM pivotal study published in the Journal of Clinical Sleep Medicine demonstrated Genio's clinical efficacy, differentiating it from competitors [6] - The company closed 2025 with a global gross revenue of EUR 11 million, driven by strong Q4 U.S. launch momentum [6] Q&A Session Summary Question: Update on VAC submissions and account activations - Management confirmed 120 VAC submissions with 57 approvals, expecting more approvals in Q1 2026 [21][22] Question: Timing for ACCESS study data and PMA supplement submission - The 12-month data will be available by the end of June 2026, with submission planned for Q1 2027 [24] Question: Cash burn rate and guidance for 2026 - Cash burn is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases [29] Question: Competitor's coding strategy and implant numbers - Management indicated plans to pursue dedicated coding for Genio by 2028, while not disclosing specific implant numbers [31][33] Question: Key drivers for Genio adoption among physicians - Surgeons are attracted to Genio's unique features, including bilateral stimulation and a single incision procedure [51]

Financial Data and Key Metrics Changes - For Q4 2025, gross revenue was EUR 6.3 million before EUR 700,000 of revenue deferrals, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [14] - Full year 2025 gross revenue was EUR 11 million before EUR 1 million of revenue deferrals, resulting in net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [15] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [14][15] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024, while the full year operating loss increased to EUR 83.5 million from EUR 58.8 million in 2024 [14][15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million of revenue generated from the first full quarter of launch [14][5] - 145 surgeons were trained in 125 high-volume hypoglossal nerve stimulation accounts, with 57 receiving positive Value Analysis Committee approval [5][7] - The company reported consistent reimbursement from both commercial payers (approximately 90% of business) and Medicare (10% of business) during Q4 [9][10] Market Data and Key Metrics Changes - The company closed 2025 with a global gross revenue of EUR 11 million, driven by strong momentum from the U.S. launch [6] - Internationally, growth continued in selected markets, including Germany, the United Kingdom, and the Middle East, with Germany being the first international market to reach profitability [12] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - The company is expanding its internal manufacturing footprint to strengthen its competitive position and improve gross margins [17] - The company plans to submit a PMA supplement for the ACCCESS study data by the end of July 2026, potentially leading to U.S. label expansion in early 2027 [24][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, emphasizing the positive feedback from surgeons and patients regarding Genio's unique features [8][12] - The reimbursement environment is viewed as a normal maturation of an established therapy, with clarity on facility fees expected to support further adoption of Genio [11] - The company anticipates a sequential growth of 25% in U.S. net revenue for the first and second quarters of 2026, driven by continued surgeon training and growing adoption [16] Other Important Information - The company reported a cash position of EUR 48 million as of December 31, 2025, with an expected cash burn rate of approximately EUR 20 million per quarter in the near term [15][29] - The introduction of new C-codes for AGNS by CMS is expected to facilitate billing for traditional Medicare patients, aligning reimbursement for Genio with competitors [10][9] Q&A Session Summary Question: Can you provide an update on the remaining VAC processes and new account activations? - Management confirmed that 120 VAC submissions were made, with 57 approved, and expects the remaining approvals to occur in Q1 2026 [20][21] Question: What is the timeline for the ACCCESS study data and PMA supplement submission? - The 12-month data will be available by the end of June 2026, with analysis taking up to 30 days, leading to a PMA supplement submission by the end of July 2026 [23][24] Question: What is the cash burn rate and guidance for 2026? - The cash burn rate is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases in the U.S. [29] Question: How many implants have been performed, and what is the approach to inventory? - Management clarified that they do not disclose precise implant numbers but indicated that revenue generated in Q4 suggests a significant number of implants were performed [33][34] Question: What are the key drivers for Genio adoption among physicians? - Key drivers include the optionality provided by Genio, its single incision technique, and bilateral stimulation, which resonate well with surgeons [50][51]

Financial Data and Key Metrics Changes - In Q4 2025, gross revenue was EUR 6.3 million before deferrals, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [13] - For the full year 2025, gross revenue was EUR 11 million, leading to net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [14] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [13][14] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024 [13] - Total operating loss for the full year 2025 was EUR 83.5 million, up from EUR 58.8 million in 2024, reflecting increased commercialization activities [14][15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million in revenue generated from the first full quarter of launch [13][5] - 145 surgeons were trained across 125 high-volume hypoglossal nerve stimulation accounts in the U.S. [6] - 57 Value Analysis Committee approvals were received, with no rejections to date [6][7] Market Data and Key Metrics Changes - The U.S. market is the primary growth driver, with international markets contributing consistently, particularly in Germany, the UK, and the Middle East [12] - Medicare reimbursement for Genio has been consistent, representing 10% of the business, while commercial payers account for approximately 90% [9][10] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - Plans include expanding internal manufacturing to strengthen competitive position and improve gross margins [17] - The company is preparing for a PMA supplement submission based on 12-month ACCCESS study data, potentially leading to U.S. label expansion in early 2027 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, with expectations of 25% sequential growth in U.S. net revenue for Q1 and Q2 2026 [16] - The reimbursement environment is viewed as a normal maturation of an established therapy, with clarity on facility fees expected to support further adoption [11] Other Important Information - The company has a cash position of EUR 48 million as of December 31, 2025, with an expected cash burn of approximately EUR 20 million per quarter in the near term [15][30] - The introduction of new C-codes for AGNS by CMS is anticipated to facilitate billing for traditional Medicare patients [10] Q&A Session Summary Question: Status of Value Analysis Committee submissions and account activations - Management confirmed 120 VAC submissions with 57 approvals, expecting more approvals in Q1 2026 [20][21] Question: Timing for ACCCESS study data and PMA supplement submission - The 12-month data will be available by the end of June 2026, with submission planned for Q1 2027 [23][25] Question: Cash burn rate and guidance for 2026 - Cash burn is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases [29][30] Question: Competitor's coding strategy and implant numbers - Management indicated plans to pursue dedicated coding for Genio, with no specific implant numbers disclosed but revenue figures suggest a strong sales performance [31][34] Question: Patient demographics for Genio implants - Patients are primarily coming from established referral networks, with many choosing Genio for its minimally invasive design and upgradeable features [59]

Summary of Nyxoah's Conference Call Company Overview - **Company**: Nyxoah - **Industry**: MedTech, specifically focused on the treatment of obstructive sleep apnea (OSA) through neuromodulation solutions - **Market Opportunity**: The U.S. OSA market is valued at approximately $10 billion, identified as a blockbuster market with significant under-penetration [2][3] Core Points and Arguments - **FDA Approval**: Nyxoah has received FDA approval and is actively launching its product in the U.S. market [2] - **Technology Differentiation**: The Genio system offers a unique bilateral mode of action, which is minimally invasive and does not require an implanted battery, making it distinct from competitors [3][9] - **Clinical Evidence**: The DREAM study demonstrated a 63.5% reduction in the Apnea-Hypopnea Index (AHI) and a 71.3% oxygen desaturation responder rate, indicating strong efficacy and safety [15][16] - **Market Penetration**: Nyxoah has implanted over 1,000 patients in Europe and is commercially reimbursed in several countries, including Germany, the U.K., and the UAE [3][19] - **U.S. Commercial Strategy**: The company focuses on high-volume hypoglossal nerve implanting accounts, which represent about 70% of the total market volume in the U.S. [19][20] - **Sales Team**: Nyxoah has a dedicated U.S. sales team of approximately 60 people, with 40 focused on high-volume accounts [20] Reimbursement Insights - **CPT Codes**: Nyxoah has secured CPT codes recognized by both Medicare and private payers, including major insurers like UnitedHealthcare and Blue Cross Blue Shield [22][36] - **CMS Communication**: Recent updates from CMS indicate that both Genio and its competitors will receive a facility fee of $31,526 for implants, ensuring continued reimbursement [37][40] - **Market Dynamics**: There is a clear need for dedicated codes for hypoglossal nerve stimulation (HGNS) as the market evolves with multiple technologies [36][37] Competitive Landscape - **Demand Drivers**: The demand for Genio is driven by physician and patient needs for alternatives to battery-implanted devices, as well as the clinical superiority of the Genio system in treating complex airway obstructions [29][30] - **Patient Preferences**: Patients prefer the discreet single incision and the absence of a battery replacement requirement, which enhances the appeal of Genio [32] Financial Outlook - **Revenue Break-Even**: Nyxoah aims to achieve revenue break-even at approximately EUR 150 million, with an expected gross margin of over 80% [42] - **Operational Leverage**: The company has built out its organization to scale effectively, with limited direct-to-consumer (DTC) spending compared to competitors [43] Additional Insights - **Geographic Expansion**: Nyxoah is selectively expanding into international markets, with plans to enter Singapore and other Asian markets [24] - **Patient Engagement**: The Genio system includes a smart wearable component and an app for monitoring sleep data, enhancing patient involvement and data collection for healthcare management [12][13] Conclusion - Nyxoah is positioned as a significant player in the OSA treatment market with a differentiated technology, strong clinical evidence, and a focused commercialization strategy. The company is navigating the complexities of reimbursement while expanding its market presence and enhancing its product offerings [25][36]

Core Viewpoint - Nyxoah's Genio system has received a significant reimbursement boost from Medicare, enhancing its commercial viability in the U.S. market, particularly in outpatient settings where Medicare is prevalent [2][4]. Product and Technology Mechanism - Genio utilizes hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) by stimulating the hypoglossal nerve to maintain airway patency, serving as a key alternative to CPAP [6]. - The system features a single incision implantation, reducing surgical trauma and time, with reimbursement rates for outpatient hospitals (HOPD) increased to $45,000 (up approximately 48% from 2025) and for ambulatory surgical centers (ASC) to $42,373 (up approximately 58%) [6][12][17]. - Genio's wireless and external energy supply design avoids complications associated with wires, lowering long-term maintenance costs and repair risks [9][12]. - The selective stimulation design allows for precise control over the movement of the tongue, enhancing the effectiveness of the treatment [13]. CMS Reimbursement Changes - The reclassification of CPT 64568 into the new technology payment category APC 1580 significantly improves reimbursement levels, lowering economic barriers for healthcare providers to adopt Genio [14]. - The increased reimbursement aligns with the trend towards outpatient procedures, making Genio suitable for ASC environments, which are becoming more prevalent [15]. - The patient demographic for OSA overlaps significantly with Medicare beneficiaries, making robust Medicare reimbursement critical for HNS adoption [19]. Competitive Landscape - Nyxoah's primary competitor is Inspire Medical, which has established a dominant market position. However, Genio's unique technology and surgical process differentiate it from Inspire [20]. - Genio's single incision and wireless design make it more suitable for ASC settings, contrasting with Inspire's reliance on hospital resources due to its more complex implantation process [21][22]. - The external energy supply of Genio allows for future innovations and personalized treatments, creating a distinct market position compared to Inspire's implanted power source [23]. Industry Insights - The reimbursement increase reflects a broader trend in the HNS market, indicating a shift from CPAP reliance to more advanced surgical techniques for OSA treatment [24].

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was EUR 2 million, a 56% increase from EUR 1.3 million in Q3 2024 [12] - Gross margin decreased to 60.5% in Q3 2025 from 62% in Q3 2024 [12] - Total operating loss increased to EUR 24.4 million in Q3 2025 from EUR 15 million in Q3 2024, attributed to increased commercial investments in the U.S. [12] - Cash position decreased to EUR 22.5 million at September 30, 2025, down from EUR 43 million at June 30, 2025 [12] - The company secured up to $77 million in capital to support U.S. commercialization efforts [13] Business Line Data and Key Metrics Changes - The first commercial Genio implant in the U.S. generated $231,000 in revenue during Q3 2025 [5] - 15 implants were performed across nine accounts in the U.S. by the end of October 2025 [24][25] - 111 surgeons were trained on Genio, and 102 value analysis committee submissions were completed, with 35 approvals received [6][7] Market Data and Key Metrics Changes - The company is focused on expanding its U.S. commercial organization and has secured reimbursement with Medicare and 10 private payers [9][10] - The company is also driving deeper penetration in Germany and the UK, while selectively expanding into the Middle East [11] Company Strategy and Development Direction - The company aims to manage obstructive sleep apnea (OSA) as a chronic condition, integrating AI and self-learning into future Genio products [15] - The focus is on expanding the U.S. commercial organization and training more surgeons to activate more accounts [11] - The company is positioned to differentiate itself in the market by offering a bilateral stimulation solution that respects the anatomy of the hypoglossal nerve [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch, noting strong enthusiasm from physicians and patients for the Genio solution [4] - The company anticipates continued progress in securing coverage decisions from additional commercial payers [10] - The fourth quarter 2025 revenue is expected to be between EUR 3.4 million and EUR 3.6 million, reflecting ongoing growth in both U.S. and international markets [14] Other Important Information - The company has achieved a 100% approval rate on prior authorization submissions through its GEMIO access program [9] - The inclusion of CPT code 64568 in medical policies by major payers is expected to streamline patient access [10] Q&A Session Summary Question: Feedback from doctors and patients on choosing Genio - Physicians appreciate the optionality Genio provides and its bilateral stimulation solution, which is effective for complex airway obstructions [18] Question: Status of sales force build-out - The company is focused on high-volume AGNS sites and plans to add up to 15 territory managers quarterly to cover all 400 high-volume implant sites [19] Question: Number of implants and U.S. revenue in Q3 - A total of 15 implants were performed through the end of October, generating EUR 231,000 in revenue [24][25] Question: Guidance for U.S. versus international revenue - The company is not breaking out U.S. versus international revenue at this time, as it is still in the early phases of account activation in the U.S. [26] Question: Appeal of Genio among different demographics - Genio appeals to both male and female patients, with a focus on younger individuals who value the implant for life concept [35] Question: KPIs for future reporting - The company plans to provide updates on the number of surgeons trained and accounts that have implanted, while potentially dropping value analysis committee metrics in the future [41] Question: Pricing and average selling price (ASP) - The average selling price for implants is around $25,000, with expectations for U.S. revenue to grow from October to December [47][48] Question: Impact of U.S. rollout on gross margins - Long-term gross margins are expected to reach the 80% range, with improvements anticipated from the next-generation Genio and increased production volumes [50][52] Question: Phasing of reimbursement progress - The CPT code 64568 is expected to remain in use for the long term, providing a clear pathway for reimbursement with both Medicare and commercial payers [58][59]

Summary of Nyxoah Conference Call Company Overview - **Company**: Nyxoah - **Industry**: Hypoglossal Nerve Stimulation (HG&S) for Obstructive Sleep Apnea (OSA) Key Points Commercial Launch and Structure - Nyxoah launched its Genio device on August 11, with a focus on high-volume accounts in the U.S. market [3][6] - Currently, there are approximately 1,500 implanting accounts, with 400 accounts generating 75% of the volume [3][11] - The commercial team consists of 25 territory managers targeting 125 high-volume accounts, with plans to add 75 new accounts each quarter [6][11] - The strategy emphasizes quality over quantity, focusing on high-volume centers of excellence [11][12] Training and Surgeons - As of now, 121 surgeons have been trained across the 125 targeted accounts, indicating strong momentum [17][18] - Feedback from surgeons highlights the optionality and clinical differentiation of Genio compared to existing treatments [18][24] Patient Identification and Demand - The target patient demographic includes those who prefer not to have a battery implanted and those with positional OSA [23][24] - There is a noted pre-existing demand for Genio among patients who previously opted out of traditional implants [25][26] Surgical Proficiency and Time - The average surgical time has decreased from 90 minutes for initial procedures to around 60 minutes as surgeons gain experience [29][30] - The fastest recorded implant was completed in 32 minutes by an experienced surgeon [30] Reimbursement and Payer Relationships - All reimbursement submissions to Medicare and private payers have been approved, with no rejections reported [32][33] - Major payers like Blue Cross Blue Shield and UnitedHealth have accepted the reimbursement code for Genio [32][34] Financial Strategy and Funding - The company is focusing investments on U.S. commercial launch and innovation while managing cash burn effectively [41][42] - Plans to raise capital to support four to five quarters of commercial success are in place [42] Future Opportunities and Trials - The Axis trial for the triple C indication has stopped enrollment, with potential label approval expected by late 2026 or early 2027 [45][46] - Nyxoah aims to differentiate itself from competitors by focusing on innovative platforms rather than traditional pacemaker solutions [47][48] GLP-1 Impact - The introduction of GLP-1 medications is seen as a positive development, potentially increasing the patient pool for OSA treatments [60][63] - Nyxoah's strategy focuses on managing chronic diseases and improving patient outcomes through innovative solutions [61][63] Next Generation Technology - Future developments aim to eliminate wearable components, incorporating self-learning systems for patient convenience [67][68] - By 2030, Nyxoah expects to offer devices without any wearable components, enhancing user experience [68] Additional Insights - The company emphasizes the importance of patient management and setting correct expectations for treatment outcomes [59][61] - Nyxoah's approach to OSA treatment is positioned as a long-term chronic disease management strategy, focusing on patient ownership and compliance [48][61]

Company Expansion - Nyxoah SA announced the expansion of its commercial footprint in the Middle East following the first successful Genio implant in Abu Dhabi in September 2025 [1][9] - The company aims to partner with healthcare institutions in Dubai, Kuwait, and Abu Dhabi to enhance access to the Genio system for OSA patients who cannot tolerate CPAP [3][9] Product Overview - Genio is the only leadless, externally powered bilateral hypoglossal nerve stimulation system for treating moderate-to-severe obstructive sleep apnea (OSA) [1][9] Market Potential - The global sleep apnea devices market was valued at $4.5 billion in 2023 and is projected to reach $6.9 billion by 2030, growing at a CAGR of 6.2% [4] - Factors driving market growth include an aging population, a significant patient pool with sleep apnea, and increased prevalence of comorbidities associated with sleep apnea [4] Competitive Landscape - Inspire Medical Systems reported strong revenue growth and market penetration in its second-quarter results, indicating a competitive environment in the OSA space [7] - Resmed Inc. launched the Sleep Institute to advance sleep health, reflecting ongoing innovation and focus in the industry [8][10] - LivaNova PLC initiated the commercial launch of the Essenz Perfusion System in China and reported solid revenue growth, showcasing competitive dynamics in the market [11]

Summary of Nyxoah (NYXH) 2025 Conference Call Company Overview - **Company Name**: Nyxoah - **Industry**: Medical Technology (MedTech) - **Focus**: Innovative solutions for treating obstructive sleep apnea (OSA) patients - **Key Product**: Genio solution, which received FDA approval on August 8, 2025, and launched in the U.S. on August 11, 2025 [6][20] Market Insights - **Obstructive Sleep Apnea Market**: - Significant market with millions of patients in the U.S. suffering from moderate to severe OSA [5][7] - The market is described as having "blockbuster potential" due to the large number of eligible patients for treatment [9] - **Current Treatment Landscape**: - CPAP (Continuous Positive Airway Pressure) is the gold standard but has a compliance issue, with nearly 50% of patients discontinuing use after 2-3 years [10][11] - Genio aims to fill the gap for patients who cannot tolerate CPAP [19] Product Differentiation - **Genio Device Mechanism**: - Utilizes bilateral stimulation to maintain airway openness during sleep by contracting the genioglossus muscle [12][14] - No implantable battery, making it more patient-friendly and MRI compatible [14][15] - Software updates can be performed without surgery, enhancing user experience [15] Commercial Strategy - **U.S. Market Entry**: - Focused launch strategy targeting high-volume centers and establishing relationships with key customers [20][26] - Initial revenue expected to ramp up in 2026, with foundational work being done in 2025 [27][28] - **Operational Expenditures**: - R&D spending expected to increase in the mid-single digits percentage-wise compared to the previous year [30] - SG&A expenses projected to rise by 66-75% due to investments in the U.S. commercial organization [31] Financial Outlook - **Current Cash Position**: - €43 million in cash as of June, with a reduced cash burn from €23 million to €20 million in Q2 [38][39] - Sufficient cash to sustain operations into 2026, with plans to evaluate capital-raising options [40] - **Revenue Breakeven Point**: - Estimated to be around $200 million, which is lower than competitors, allowing for a more targeted commercialization approach [41] Future Developments - **Data Collection and Registry**: - Plans to establish a registry to collect patient data and health economic data to support payer negotiations [32][34] - **Future Product Iterations**: - Development of a smart implant capable of automatic adjustments and a closed-loop system for enhanced patient experience [35][36] Key Takeaways - Nyxoah is positioned to capitalize on a significant market opportunity in the OSA space with its innovative Genio solution - The company is focused on building a strong commercial presence in the U.S. while managing operational expenditures effectively - Future growth will depend on successful market penetration, patient compliance, and ongoing product development initiatives [6][20][27]